Daily Sepsis Research Analysis
Analyzed 25 papers and selected 3 impactful papers.
Summary
Three impactful sepsis studies stand out: a multi-omic analysis identifies a terminally differentiated FOLR3+ neutrophil subset, HIF-1A–driven, that exacerbates hyper-inflammation and predicts 28-day mortality; a contextualized telesimulation program in a Ghanaian pediatric ED is associated with markedly lower mortality and improved time-critical processes; and a large Japanese claims study shows no mortality benefit from broad- versus narrow-spectrum empiric antibiotics in acute cholangitis, with longer LOS and IV therapy in the broad group.
Research Themes
- Precision immunophenotyping and prognostic biomarkers in sepsis
- Implementation science and telesimulation for pediatric sepsis care in LMICs
- Antimicrobial stewardship in biliary sepsis/acute cholangitis
Selected Articles
1. FOLR3+neutrophils contribute to sepsis by exacerbating hyper-inflammation.
Integrated single-cell and bulk transcriptomics identified a terminally differentiated, hyper-inflammatory FOLR3+ neutrophil subset enriched in non-survivors. Computational and experimental data implicate HIF-1A as a key driver, with FOLR3+ neutrophils recruiting platelets and secreting pro-inflammatory cytokines; higher FOLR3+ levels correlated with 28-day mortality.
Impact: This study reveals a mechanistically distinct neutrophil phenotype (FOLR3+) that links to mortality and identifies HIF-1A as a regulator, opening avenues for biomarker development and targeted immunomodulation.
Clinical Implications: While not yet practice-changing, FOLR3+ neutrophils may evolve into a prognostic biomarker and therapeutic target; assays quantifying this subset could aid risk stratification and inform trials of HIF-1A/FOLR3-pathway modulation.
Key Findings
- Five neutrophil clusters were identified; FOLR3+ neutrophils were predominant, terminally differentiated, hyper-inflammatory, and exhibited low HLA expression, especially in non-survivors.
- CellChat analysis suggested FOLR3+ neutrophils promote sepsis progression via platelet recruitment through RETN–CAP1 and NAMPT–ITGB1 signaling axes.
- External validation associated higher proportions of FOLR3+ neutrophils with increased 28-day mortality in sepsis.
- HIF-1A emerged as the key transcriptional driver; manipulating HIF-1A in human/mouse neutrophils altered FOLR3 expression and secretion of IL-1β, TNF-α, IL-8, and IL-6.
Methodological Strengths
- Integration of single-cell and bulk RNA-seq with computational cell–cell communication analyses
- External validation and functional perturbation (HIF-1A overexpression/knockout) across human and mouse neutrophils
Limitations
- Primarily observational transcriptomic data; causal pathways in vivo remain to be confirmed
- Generalizability and standardization of FOLR3+ neutrophil quantification for clinical use are not established
Future Directions: Prospective, multicenter validation of FOLR3+ neutrophils as a prognostic biomarker; interventional studies targeting HIF-1A/FOLR3+ pathways to modulate hyper-inflammation in sepsis.
Sepsis severity is associated with sustained neutrophilia, yet the underlying heterogeneity remains unclear. By integrating single-cell and bulk RNA-seq of septic peripheral blood, we uncovered five neutrophils clusters. FOLR3+neutrophils were the predominant and terminally differentiated subgroup, which displayed hyper-inflammatory signatures and low HLA expression, especially in non-survivors of sepsis. Cell-chat analysis also showed these neutrophils could promote sepsis progression by recruiting platelet via RETN-CAP1 and NAMPT-ITGB1 axes. External validation found that higher FOLR3+neutrophils were associated with 28-day mortality of sepsis.
2. Pediatric Emergency Department Care for Septic Shock in Sub-Saharan Africa: Single-Center Outcomes Before-Vs.-After Implementation of a Telesimulation Program, 2023-2024.
In a 12-month, single-center before–after study in Ghana, a contextualized, low-bandwidth telesimulation program for pediatric ED providers was associated with lower mortality (10% post vs 36% pre; OR 0.2, 95% CI 0.1–0.5) and improved care processes (greater use of oxygen and IV access). Acceptability and feasibility were high among trainees (44/45).
Impact: Demonstrates a scalable, context-adapted training model that measurably improves pediatric sepsis outcomes and processes in a low-resource setting.
Clinical Implications: Remote, low-bandwidth telesimulation with local content can rapidly upskill ED teams, improving time-critical interventions and reducing mortality in pediatric sepsis; programs should be integrated with monitoring for sustainability and equity.
Key Findings
- Mortality decreased from 36% (25/70) pre-implementation to 10% (7/67) post-implementation (OR 0.2, 95% CI 0.1–0.5; p=0.001).
- Improved care processes post-implementation: higher odds of supplemental oxygen (OR 2.4; 95% CI 1.0–5.7) and IV placement (OR 3.8; 95% CI 1.3–13.1).
- High acceptability and feasibility among trainees (44/45 agreed).
Methodological Strengths
- Prospective quasi-experimental before–after design with trained observers capturing time-critical processes
- Contextualized, low-bandwidth intervention and validated surveys assessing acceptability/feasibility
Limitations
- Single-center, nonrandomized design with modest sample size; residual confounding possible
- Short-term, in-hospital outcomes without long-term follow-up or cost-effectiveness assessment
Future Directions: Cluster-randomized or stepped-wedge multicenter trials to confirm effectiveness, examine sustainability, and assess cost-effectiveness and long-term patient-centered outcomes.
OBJECTIVES: Sepsis is a leading cause of preventable death in low-resource settings, where delays in recognition and emergency department (ED) treatment are common. Limited access to training also contributes to poor outcomes. We hypothesized that a contextualized telesimulation and debriefing program would be associated with better sepsis-related outcomes and time-critical care processes in children presenting to our center in Kumasi, Ghana. We also determined the program's acceptability and feasibility in our clinical providers. DESIGN: We conducted a 12-month mixed-method quasi-experimental (before vs. after implementation) study at Komfo Anokye Teaching Hospital, 2023-2024. Pediatric ED providers completed 30-minute, low-bandwidth telesimulation sessions using culturally-adapted real patient videos, filmed in the local Ghanaian hospital. Clinical outcomes and care processes were evaluated pre- and post-intervention. Trained observers recorded time-critical interventions: shock recognition, oxygen use, IV access, fluid bolus, reassessment, blood cultures, and antibiotics. Acceptability and feasibility were assessed using validated surveys.
3. Clinical impact of broad- versus narrow-spectrum empiric therapy in acute cholangitis: A Japanese claims database study.
Among 4,755 Japanese claims-identified acute cholangitis cases undergoing drainage, broad-spectrum empiric therapy showed no association with lower 30-day in-hospital mortality versus narrow-spectrum therapy in both multivariable and propensity-matched analyses. Broad-spectrum therapy was linked to longer IV antibiotic duration (+1 day) and longer length of stay (+3 days).
Impact: Provides large-scale, real-world evidence challenging routine use of broad-spectrum empiric antibiotics in acute cholangitis, supporting stewardship without compromising mortality.
Clinical Implications: Initial empiric therapy can often be narrow-spectrum aligned with local epidemiology when prompt drainage is achieved; de-escalation strategies may reduce treatment duration and LOS without harming survival.
Key Findings
- Broad-spectrum empiric therapy was not associated with reduced 30-day in-hospital mortality vs narrow-spectrum (adjusted OR 1.37; 95% CI 0.84–2.23).
- Propensity score-matched analysis confirmed no mortality benefit (OR 1.43; 95% CI 0.82–2.50).
- Broad-spectrum therapy was associated with longer IV antibiotic duration (+1 day; 95% CI 0.31–1.69) and longer hospital stay (+3 days; 95% CI 1.87–4.13).
- Mortality risk increased with older age, higher Charlson index, presence of sepsis, and ICU admission.
Methodological Strengths
- Large real-world cohort with multivariable adjustment and propensity score matching
- Consistent findings across analytic approaches and clinically relevant endpoints
Limitations
- Retrospective claims data prone to residual confounding and misclassification
- Limited microbiologic granularity and no randomized allocation of empiric regimens
Future Directions: Prospective, microbiology-informed trials to refine empiric choices, evaluate rapid diagnostics, and integrate stewardship with timing of source control.
The clinical benefit of broad-spectrum empiric therapy in patients with acute cholangitis is unclear. We aimed to evaluate the impact of broad-spectrum and narrow-spectrum empiric therapies on patient outcomes using a Japanese claims database. The study included patients who were diagnosed with acute cholangitis between April 2014 and August 2022, aged 18-99 years, received antibiotics, had blood cultures collected, and underwent biliary drainage. Patients who received empiric therapy with carbapenems, piperacillin/tazobactam, or fourth-generation cephalosporins were included in the broad-spectrum group, whereas others were included in the narrow-spectrum group. Of the 4,755 eligible patients, 3,377 were categorized into the narrow-spectrum group and 1,378 into the broad-spectrum group. In the multivariate logistic regression analysis, older age, higher Charlson Comorbidity Index, the presence of sepsis, and intensive care unit admission were associated with increased 30-day in-hospital mortality, whereas the receipt of broad-spectrum empiric therapy was not (adjusted odds ratio, 1.37 [95% confidence interval {CI}, 0.84-2.23]).